WHO淋巴结、脾及胸腺细胞病理报告系统的实践意义:基于模式的方法对FNA活检血液淋巴肿瘤分型的分类与辅助检测
该综述概述了新近发表的WHO淋巴结、脾及胸腺细胞病理报告系统(WHO系统),该系统通过五类诊断分组标准化血液淋巴组织细针穿刺活检的诊断方法,每类关联明确恶性风险。系统整合细胞形态学特征与临床背景,并常需流式细胞术、免疫细胞化学、原位杂交和分子诊断等辅助技术。综述深入讨论了基于模式的诊断方法,强调临床相关性和辅助技术应用的重要性。
要点
- WHO系统将标本分为五类:不足/不充分/无法诊断、良性、非典型、可疑恶性、恶性。
- 每类诊断分组关联明确的恶性风险,支持临床决策。
- 基于四种细胞病理学模式的诊断方法有助于缩小鉴别诊断范围。
核心结论
- WHO系统为血液淋巴组织细针穿刺活检提供结构化诊断框架,增强诊断清晰度并促进细胞病理学家与临床医生沟通。
研究设计与样本
- 综述,概述WHO系统及其在血液淋巴增殖性疾病中的应用,并深入讨论基于模式的诊断方法。
主要发现
- WHO系统将标本分为五类诊断分组,每类关联明确恶性风险。
- 四种细胞病理学模式(混合淋巴细胞;以小/中间细胞为主;以大/多形/母细胞为主;单个、非常大、非典型细胞)作为缩小鉴别诊断的指南。
- 由于特征重叠、炎症背景多变和样本材料有限,判读可能具有挑战性。
关键数值与推荐
- 五类诊断分组:不足/不充分/无法诊断、良性、非典型、可疑恶性、恶性。
- 辅助技术包括流式细胞术、免疫细胞化学、原位杂交和分子诊断。
临床怎么用
- 整合细胞形态学特征与临床背景进行准确分类。
- 使用流式细胞术、免疫细胞化学、原位杂交和分子诊断等辅助技术进行最终和具体诊断。
- 应用基于模式的诊断方法缩小鉴别诊断范围。
局限性
- 特征重叠、炎症背景多变和样本材料有限可导致判读困难。
- 细胞病理学评估在血液淋巴肿瘤中具有优势和局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of the recently published World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology (WHO system) is to standardize the diagnostic approach to fine-needle aspiration biopsies of hematolymphoid tissues. By categorizing specimens into five diagnostic groups-inadequate/insufficient/nondiagnostic, benign, atypical, suspicious for malignancy, and malignant-the system provides a structured framework that enhances diagnostic clarity and facilitates communication between cytopathologists and clinicians. Each category is associated with a defined risk of malignancy, supporting informed clinical decision making regarding further diagnostic workup. Accurate categorization requires the integration of cytomorphologic features and clinical context, and final and specific diagnoses often require ancillary techniques such as flow cytometry, immunocytochemistry, in situ hybridization, and molecular diagnostics. To assist cytopathologists, especially those less familiar with hematolymphoid neoplasms, the WHO system incorporates a pattern-based diagnostic approach. Four cytopathologic patterns-mixed lymphoid cell; predominantly small/intermediate cell; predominantly large/pleomorphic/blastic cell; and single, very large, atypical cell-serve as guides to narrow down differential diagnoses. However, interpretation can be challenging because of overlapping features, variable inflammatory backgrounds, and limited sample material. This review provides a brief overview of the WHO system and its application to hematolymphoid proliferations, emphasizing the importance of clinical correlation and the use of relevant ancillary techniques. It then provides in-depth discussion of the pattern-based approach to diagnosing hematolymphoid neoplasms on cytopathology. It highlights the strengths and limitations of cytopathologic evaluation in hematolymphoid neoplasms and provides practical insights for applying the WHO system in routine practice.
引用
- Ehinger M, Calaminici M, Cozzolino I, et al. Practical implications of the World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Categories and ancillary testing for subtyping of hematolymphoid tumors on FNA biopsy cytopathology using a pattern-based approach. Cancer Cytopathol. 2026. PMID: 41432088. doi:10.1002/cncy.70066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。